CorMedix Inc. (CRMD)
| Market Cap | 371.44M -58.1% |
| Revenue (ttm) | 412.49M +92.5% |
| Net Income | 63.47M -60.7% |
| EPS | 0.72 -68.0% |
| Shares Out | 79.54M |
| PE Ratio | 6.45 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,987,742 |
| Open | 4.790 |
| Previous Close | 4.820 |
| Day's Range | 4.635 - 4.870 |
| 52-Week Range | 4.635 - 13.020 |
| Beta | 1.48 |
| Analysts | Buy |
| Price Target | 13.80 (+195.5%) |
| Earnings Date | Nov 12, 2026 |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CRMD stock is "Buy." The 12-month stock price target is $13.8, which is an increase of 195.50% from the latest price.
News
CorMedix Proxy statement: Proxy filing
CorMedix filed a proxy statement on November 16, 2026, providing details for shareholder voting and corporate governance matters.
CorMedix price target lowered to $13 from $15 at Oppenheimer
Oppenheimer analyst Les Sulewski lowered the firm’s price target on CorMedix (CRMD) to $13 from $15 and keeps an Outperform rating on the shares. Following Q3 results and its follow-up…
CorMedix Earnings Call Transcript: Q3 2026
Q3 revenue was $54.5M and adjusted EBITDA was $3.1M, with $355.2M in cash. FY 2026 guidance was maintained or narrowed upward, while the proposed Heron acquisition would add scale, products, and expected synergies.
CorMedix Earnings release: Q3 2026
CorMedix released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
CorMedix Quarterly report: Q3 2026
CorMedix has published its Q3 2026 quarterly earnings report on November 12, 2026.
CorMedix reports Q3 EPS (19c) vs. $1.26 last year
Reports Q3 revenue $54.52M, consensus $52.77M. Joseph Todisco, Chairman & Chief Executive Officer of CorMedix (CRMD), commented, “CorMedix will be entering 2027 with two meaningful potential growth dr...
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company ...
CorMedix price target raised to $15 from $14 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on CorMedix (CRMD) to $15 from $14 and keeps an Outperform rating on the shares. The company announced the acquisition…
CorMedix price target raised to $14 from $12 at Needham
Needham analyst Serge Belanger raised the firm’s price target on CorMedix (CRMD) to $14 from $12 and keeps a Buy rating on the shares. The firm is adjusting its model…
CorMedix Proxy statement: Proxy filing
CorMedix filed a proxy statement on November 10, 2026, providing details for shareholder voting and corporate governance matters.
CorMedix Transcript: M&A announcement
The asset purchase adds four commercial products and a development agreement, with ~$150 million in trailing 12-month net product revenue. Management expects immediate accretion and $45 million-$60 million in annualized synergies by year-end 2027.
CorMedix Press release: M&A announcement
CorMedix issued a press release on November 9, 2026, disclosing material business information to investors.
CorMedix Slides: M&A announcement
CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
CorMedix to acquire Heron Therapeutics for $145M in cash upfront
CorMedix (CRMD) and Heron Therapeutics (HRTX) announced that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron, an...
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 mil...
CorMedix Proxy statement: Proxy filing
CorMedix filed a proxy statement on November 9, 2026, providing details for shareholder voting and corporate governance matters.
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, befor...
CorMedix backs FY26 revenue view $325M-$345M, consensus $336.59M
The company said, “On October 28, 2026, CMS released the 2027 End-Stage Renal Disease Prospective Payment System final rule, which provided for a post-TDAPA Add-on for DefenCath of $8.32 per…
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to di...
CorMedix announces FDA acceptance for Priority Review of Rezzayo sNDA
CorMedix (CRMD) announced that the FDA has accepted for filing the supplemental new drug application, or sNDA, seeking approval of Rezzayo for the prophylaxis of invasive fungal disease. The sNDA…
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New D...
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the...
CorMedix initiated with an Outperform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of CorMedix (CRMD) with an Outperform rating and $15 price target Investors appear “overly focused” on DefenCath’s near-term post-TDAPA revenue decl...
CorMedix Transcript: Wells Fargo 21st Annual Healthcare Conference
The company has rapidly evolved into a diversified specialty pharma with eight marketed products and a scalable institutional platform. DefenCath's reimbursement transition and Medicare Advantage focus, REZZAYO's expanded market potential, and robust financials position the firm for further growth and strategic acquisitions.
CorMedix Slides: Corporate presentation
CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.